ReviewCurrent microbiology2026
Gut Bacteria: A Beneficial Symbiosis or a Hidden Threat? Investigating the Dual Role of Bacteria in Gastrointestinal Diseases.
Review in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The intestinal microbiota is a highly dynamic and intricate system that supports digestive function, modulates immune responses, and protects against gut disorders. This review explores the impact of gut microorganisms on gastrointestinal conditions, including irritable bowel syndrome (IBS), Crohn's disease (CD), ulcerative colitis (UC), and colorectal cancer (CRC). Beneficial microbiota such as Lactobacillus, Bifidobacterium, Faecalibacterium, and Akkermansia help reduce inflammation and maintain intestinal homeostasis by producing short-chain fatty acids (SCFAs). These metabolites regulate immune mechanisms and reinforce the gut barrier while also suppressing harmful pathogens. In contrast, pathogenic bacteria including Fusobacterium nucleatum, Escherichia coli, Bacteroides fragilis, and Clostridium difficile contribute to gastrointestinal disorders by producing toxins, increasing mucosal permeability, and stimulating inflammatory responses. Additionally, microbial dysbiosis-alterations in microbiota composition-can lead to chronic inflammation and neoplastic changes in intestinal cells, thereby promoting CRC development. Future studies may further clarify microbiota-pathogen interactions, which may provide a basis for exploratory therapeutic strategies.
Indexed as
Identifiers
42274808What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.